Business
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases Highlights ITK inhibition novel mechanism of action affecting T cell receptor signaling and T cell differentiation Presented in an oral session at the 67th Am
About this update from Corvus Pharmaceuticals, Inc.
[{"type":"image","alt":"Corvus Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Corvus Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/0c48ecf7a8b7010ea2641e33fdb6724a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aOq6Ap2mYOyctX3DvsKQtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0c48ecf7a8b7010ea2641e33fdb6724a","width":300,"height":63}},"lazy":false},{"type":"text","content":"Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies","length":176,"tagName":"p"},{"type":"text","content":"Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases ","length":164,"tagName":"p"},{"type":"text","content":"Highlights ITK inhibition novel mechanism of action affecting T cell receptor signaling and T cell differentiation","length":114,"tagName":"p"},{"type":"text","content":"Presented in an oral session at the 67th American Society of Hematology Annual Meeting & Exposition","length":103,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced the presentation of final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma today in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place December 6-9, 2025 in Orlando, FL. The presentation highlights preclinical and clinical data supporting the development of soquelitinib in oncology and immune and inflammatory diseases, including data detailing its mechanism of action.","length":662,"tagName":"p"},{"type":"text","content":"“The T-cell lymphomas are devastating diseases, associated with dismal outcomes, and are thus an area of high unmet need,” said Ryan Wilcox, M.D., Ph.D., Associate Professor of Internal Medicine, University of Michigan Medical School. “In the relapsed/refractory setting, complete and durable responses are rarely achie...